Skip to content

A comparative study between spinal drug ropivacaine versus bupivacaine in planed surgery under spinal anaesthesia

A Comparative evaluation of intrathecal hyperbaric ropivacaine versus hyperbaric bupivacaine in elective surgery under spinal anaesthesia - No

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044660
Enrollment
200
Registered
2022-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 4- Measurement and Monitoring

Interventions

Intervention1: Intrathecal Hyperbaric Ropivacaine: After giving spinal anaesthesia with Hyperbaric Ropivacaine 3.5 ml intrathecal route ,we have observe the onsent of motor and sensory block and regr

Sponsors

GCS Medical College hospital and researah centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with informed consent Age between 18 to 75 Years BMI ASA I & II Infra umbilical Surgery

Exclusion criteria

Exclusion criteria: Patient who will not give consent BMI >30kg/m2 ASA III & IV Contraindication to spinal anaesthesia Known Allergy to Ropivacaine or any other local Anaesthetic Agent Duration of Surgery > 3hours Patients on chronic Anticoagulation or Antiplatelet drugs

Design outcomes

Primary

MeasureTime frame
To assess between Ropivacaine and Bupivacaine which has less cardiac and neurological complicationTimepoint: immediate after giving spinal anaesthesia

Secondary

MeasureTime frame
To assess the Hemodynamics parameters and the regression of motor and sensory effects between ropivacaine and bupivacaineTimepoint: After 4 hours of giving spinal anaesthesia

Countries

India

Contacts

Public ContactDr Ankita Patel

GCS Medical College hospital and reserach centre

drankitapatel30@gmail.com9712981484

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026